Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERUPTION
ChiCTR-IPR-17010745Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2017
- Modality
- Small Molecules, Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human prourokinase and tirofiban in myocardial infarction (MI) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Corrected TIMI frame count (cTFC) myocardial perfusion after PCI. Started Mar 2017; status: recruiting.
02
Drugs
recombinant human prourokinasetirofiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR-IPR-17010745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010745.